p53 family members and chemoresistance in cancer: what we know and what we need to know
Authors:
- 19 December 2003
- journal article
- review article
- Published by Elsevier in Drug Resistance Updates
- Vol. 6 (6) , 323-328
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Small molecules that reactivate mutant p53European Journal of Cancer, 2003
- Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed CellsMolecular and Cellular Biology, 2003
- Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differencesDrug Resistance Updates, 2003
- p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosisCancer Cell, 2003
- Akt Phosphorylates the Yes-Associated Protein, YAP, to Induce Interaction with 14-3-3 and Attenuation of p73-Mediated ApoptosisMolecular Cell, 2003
- DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target GenesMolecular Cell, 2002
- E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasiaBritish Journal of Cancer, 2002
- Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosisNature Cell Biology, 2001
- p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian CellsMolecular and Cellular Biology, 1999
- Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapyOncogene, 1999